FIGURE 3Figure 3
The expression levels of HSPG2, LOXL2, LAMB3, and SRPX genes correlate with the clinical outcomes and cell radioresistance. (A) The Kaplan-Meier analyses of the association of HSPG2, LOXL2, LAMB3, and SRPX gene expression and biochemical recurrence-free survival (BRFS) in the TCGA PRAD PC gene expression dataset (N = 407). The stratification of patients into “high” and “low” groups according to gene expression was obtained using the online tool R2 Platform ( https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=kaplan_main ). The numbers on the x -axis represent time in years. Numbers at risk are added to the bottom of each graph. (B) RT-qPCR analysis of the relative HSPG2, LOXL2, SRPX, and LAMB3 mRNA expression in DU145 P and RR cells. N = 3; Error bars = SD; ** p < 0.01; *** p < 0.001. (C) Correlation of HSPG2, LOXL2, SRPX, and LAMB3 mRNA expression levels in normal tissues (MSKCC dataset, n = 29), primary tumors (MSKCC dataset, n = 131), and metastatic tumors (MSKCC dataset,